Trial Search Results
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Stanford is currently not accepting patients for this trial.
- Radiation: stereotactic body radiation therapy
- Procedure: positron emission tomography
- Procedure: computed tomography
- Other: questionnaire administration
- Drug: fludeoxyglucose F 18
- Patients must have persistent, metastatic, or recurrent platinum resistant or
refractory ovarian or primary peritoneal cancer.
- No restriction on previous treatment regimens, but patients must be at least 2 weeks
out from last chemotherapy or investigational agent.
- Patients must be >= 18.
- Patients must have a life expectancy of at least 6 months.
- Patients must have KPS >= 60.
- Patients must have acceptable organ and marrow function as defined below (within 2
weeks prior to radiotherapy):
- leukocytes >=3,000/uL
- absolute neutrophil count >=1,500uL
- platelets >=100,000/uL
- total bilirubin within 1.5X normal institutional limits
- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels
above institutional normal
- Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT.
- Ability to understand and the willingness to sign a written informed consent document.
- Patients should not have received radiation overlapping with the proposed treatment
- Patients cannot be receiving chemotherapy or other investigation agents from two weeks
prior to radiation through undergoing their post-therapy FDG-PET/CT
- Patients cannot be pregnant or nursing.
- Patients cannot have disease >= 8cm or greater than 3 regions of disease.
- Patients cannot have concurrent malignancy other than non-melanoma skin cancer,
non-invasive bladder cancer, or carcinoma in situ of the cervix.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study